about
Helping to prioritise interventions for depression and schizophrenia: use of Population Impact MeasuresAn approach to maximizing treatment adherence of children and adolescents with psychotic disorders and major mood disordersUse of the Medication Event Monitoring System to estimate medication compliance in patients with schizophreniaA comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophreniaDuration of bed occupancy as calculated at a random chosen day in an acute care ward. Implications for the use of scarce resources in psychiatric care.Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeMedication adherence in schizophreniaCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyPerformance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Protocol for the New Medicine Service Study: a randomized controlled trial and economic evaluation with qualitative appraisal comparing the effectiveness and cost effectiveness of the New Medicine Service in community pharmacies in EnglandAn analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.Costs of treating patients with schizophrenia who have illness-related crisis eventsUnmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.The cost of relapse and the predictors of relapse in the treatment of schizophreniaInvolvement in the US criminal justice system and cost implications for persons treated for schizophrenia.Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs.Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory.Treatment compliance and noncompliance in psychoses.Prediction of the period of psychotic episode in individual schizophrenics by simulation-data construction approach.Predictors of switching antipsychotic medications in the treatment of schizophreniaAntipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Family caregivers' monitoring of medication usage: a qualitative study of Mexican-origin families with serious mental illness.Conventional versus novel antipsychotics: changing concepts and clinical implicationsDepot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort StudyAcceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing.Is phase-specific, community-oriented treatment of early psychosis an economically viable method of improving outcome?Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.A community-based perspective.Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.Preserve and strengthen family to promote mental health.Efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics.Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian populationA computerized self-report symptom distress inventory: for use as a routine clinical interview in schizophrenia.Quality of life is predictive of relapse in schizophrenia.State-of-the-art challenges for mental health services research.Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
P2860
Q24547993-77717416-CD0E-46C9-A638-C2FB715A91D7Q24644760-D981CCAC-0F28-4A0F-AFB5-DFBB6DFAC560Q24674950-9296CF26-534E-43D2-8D95-24A71B60D900Q24794849-BF38138E-ABFC-44B6-82EE-C54A384AF65DQ24814844-1B379FAB-9DE8-48C9-AD87-0BC30F81CA67Q26752965-D7E83974-D7E8-4D9A-AFB3-B9A7EDCDDBC8Q26823655-1DA3F201-A4E3-47C7-B7A5-84AF880E9BDDQ28079821-E221E64D-EE36-4548-A5BB-392102D7C59DQ30485065-C1D90AD8-9D3D-4FF6-ACF1-3D608011543AQ30571895-C2F8D6FB-9846-49E3-A74D-093B9B615730Q30590794-F83AFF8F-6304-455F-86D1-ECBDF9974C06Q30596917-E85B72F8-6928-411E-88E7-60BA3A8F8E81Q31114390-A4FD9DCA-F297-4C5B-ACEE-CB4098A7EA5EQ33268642-B03541E6-02BB-45AD-B464-70AA9C5FFDBFQ33363460-025FADB4-86CA-4B65-B9B6-ED901A05C775Q33464064-4290BC73-C421-498C-BF58-D5CC8BAC6754Q33522776-EF2F4227-061A-439E-8058-AFF00F196324Q33527102-8704A6E7-22DB-4A2B-A837-49CB4E14077CQ33543117-01BF4174-D287-48C3-A1A8-56EF2ECC5D43Q33583484-AD26DF1B-B6CE-4C3A-8CAD-BD000F992F2AQ33641662-53E8E4F5-3084-4969-9A34-4B8C05AC9895Q33655264-81C52311-0320-4A15-A781-CCF3048FF52AQ33709704-76DBD2BB-5E28-4336-B747-FF960A5276B6Q33755676-53D0747B-0CE7-4480-8833-828C3B722FF2Q33770468-2BCC8118-7F72-47F6-AC40-110405BD7A37Q33787546-4A6428F4-451A-444F-A086-CA6E2D9AA362Q33834476-C7B0543E-5AF1-43BD-8079-02516CF5AD79Q33855985-D60C600D-1D69-49FF-8F8A-375DA4ECC151Q33870572-0D6C6A7B-C511-4510-B703-161E56A005DBQ33932365-5762D071-FB2E-487C-A680-915F963070CEQ34063916-F3C8A6D6-2BB5-4274-B3C4-AA4F8A97711AQ34075734-D36B6BD4-5F7E-4D88-8A94-22373729B26FQ34078005-E9C03089-DFDF-4502-8881-FACBA43D22FEQ34082632-8E4F0679-6641-4765-A664-507071386057Q34165051-3ECB7DB1-C260-42F6-91EE-64517DE151BEQ34308009-8AD2BC1C-C7E8-449C-BCC9-16F408AC0A60Q34359774-8C973E24-AB0D-4DD2-A2B4-C5CBE3172C8AQ34542824-2E85D5BF-768F-4DEA-9968-0BE6D64BB2E0Q34609793-9ED3380E-6264-4483-9C3A-9ED7D427F51FQ34650576-2B908747-3FCF-45A4-8844-74AD313D738C
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Cost of relapse in schizophrenia.
@en
type
label
Cost of relapse in schizophrenia.
@en
prefLabel
Cost of relapse in schizophrenia.
@en
P356
P1476
Cost of relapse in schizophrenia.
@en
P2093
P304
P356
10.1093/SCHBUL/21.3.419
P407
P577
1995-01-01T00:00:00Z